A*STAR, SingHealth spin-off Bioactivx lands US$3M for next-gen wound care
For patients with serious burns, the difference between a specialist hospital and a poorly equipped clinic can shape recovery for years. Advanced wound-care products exist, but many still depend on animal-derived materials, refrigeration, sterile operating rooms and clinicians trained to handle resource-heavy procedures. In parts of Southeast Asia, where care can vary sharply between major […]…
Singapore-based Bioactivx, a spin-off from A*STAR and SingHealth, has secured US$3 million in pre-Series A funding for its next-generation wound care product, Bioactiv Matrix. The synthetic, bioinspired material aims to eliminate the need for animal-derived components, cold-chain logistics, and sterile-only applications. This could make advanced wound care more practical and accessible, particularly in Southeast Asia, where burn care occurs outside of tertiary hospitals due to various emergencies.
Bioactivx's product, which has shown promising results in preclinical and first-in-human studies, is expected to launch in Singapore by the end of 2026, with regional expansion planned for 2027. The company's founders, Dr Peili Teo and Mickey Cheong, bring extensive experience in materials science and regenerative biomaterials, respectively, while Dr Woo Yew Lok provides clinical input.
Bioactivx's platform extends beyond burns, with products planned for acute and chronic wounds, chronic ulcers, and cartilage repair.
Written by urgent.news from e27's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
